Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Linaclotide meets all endpoints in Phase III IBS trial

This article was originally published in Scrip

Executive Summary

Ironwood/Forest/Almirall's guanylate cyclase agonist linaclotide met all its primary endpoints in its first Phase III trial in irritable bowel syndrome with constipation (IBS-C).. Results from a second, ongoing trial in IBS-C are due by the end of the year. Ironwood and Forest plan to submit an NDA for the drug in the US in mid-2011. Almirall has rights to linaclotide in Europe and the Commonwealth of Independent States (CIS) and will determine EU filing dates following the completion of the second trial.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts